ID28028A - Zat-zat farmasi untuk pengobatan penyakit parkinson, adhd dan mikroadenomas - Google Patents

Zat-zat farmasi untuk pengobatan penyakit parkinson, adhd dan mikroadenomas

Info

Publication number
ID28028A
ID28028A IDW20010637A ID20010637A ID28028A ID 28028 A ID28028 A ID 28028A ID W20010637 A IDW20010637 A ID W20010637A ID 20010637 A ID20010637 A ID 20010637A ID 28028 A ID28028 A ID 28028A
Authority
ID
Indonesia
Prior art keywords
microadenomas
adhd
parkinson
treatment
pharmaceutical substances
Prior art date
Application number
IDW20010637A
Other languages
English (en)
Indonesian (id)
Inventor
Elise Rose Jackson
Stafford Mclean
Stevin Howard Zorn
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ID28028A publication Critical patent/ID28028A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IDW20010637A 1998-09-21 1999-09-03 Zat-zat farmasi untuk pengobatan penyakit parkinson, adhd dan mikroadenomas ID28028A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10119198P 1998-09-21 1998-09-21
US10386898P 1998-10-12 1998-10-12

Publications (1)

Publication Number Publication Date
ID28028A true ID28028A (id) 2001-05-03

Family

ID=26798000

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20010637A ID28028A (id) 1998-09-21 1999-09-03 Zat-zat farmasi untuk pengobatan penyakit parkinson, adhd dan mikroadenomas

Country Status (38)

Country Link
US (2) US6300329B1 (fr)
EP (1) EP1115402A1 (fr)
JP (1) JP2002526448A (fr)
KR (3) KR20040054752A (fr)
CN (1) CN1319013A (fr)
AP (1) AP1456A (fr)
AR (1) AR029739A1 (fr)
AU (1) AU760230B2 (fr)
BG (1) BG105445A (fr)
BR (1) BR9913975A (fr)
CA (1) CA2344670A1 (fr)
CO (1) CO5140075A1 (fr)
CZ (1) CZ20011006A3 (fr)
DZ (1) DZ2894A1 (fr)
EA (2) EA200100204A1 (fr)
EE (1) EE200100179A (fr)
GE (1) GEP20033081B (fr)
GT (1) GT199900154A (fr)
HN (1) HN1999000146A (fr)
HR (1) HRP20010209A2 (fr)
HU (1) HUP0103691A3 (fr)
ID (1) ID28028A (fr)
IL (2) IL164839A0 (fr)
IS (1) IS5852A (fr)
MA (1) MA26690A1 (fr)
MY (1) MY127939A (fr)
NO (1) NO20011409L (fr)
NZ (1) NZ509855A (fr)
OA (1) OA11653A (fr)
PA (1) PA8482001A1 (fr)
PE (1) PE20001084A1 (fr)
PL (1) PL346904A1 (fr)
SK (1) SK3592001A3 (fr)
TN (1) TNSN99177A1 (fr)
TR (2) TR200402083T2 (fr)
TW (1) TW518225B (fr)
WO (1) WO2000016777A1 (fr)
YU (1) YU21701A (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
US8030294B2 (en) * 2000-03-16 2011-10-04 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
GB0027020D0 (en) * 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US7132287B2 (en) 2001-06-18 2006-11-07 Psychiatric Genomics, Inc. Method for neural stem cell differentiation using 5HT-1A agonists
US20030036555A1 (en) * 2001-08-03 2003-02-20 Boehringer Ingelheim Pharma Kg Pramipexole for the treatment of ADHD
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
WO2005122767A1 (fr) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, notamment de l'uridine, utilisees dans des traitements sur des patients atteints de troubles bipolaires
WO2006020703A1 (fr) * 2004-08-11 2006-02-23 The Mclean Hospital Corporation Compose pour le traitement de la dependance, de la suppression et de l'usage de la marijuana
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
PE20070523A1 (es) 2005-09-12 2007-06-28 Wyeth Corp Formulacion de liberacion sostenida del glucuronato de (8-{4-[3-(5-fluoro-1h-indol-3-il)-propil]-piperazin-1-il}-2-metil-4h-benzo[1,4]oxazin-3-ona
GT200600416A (es) 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008083442A1 (fr) * 2007-01-10 2008-07-17 Brc Operations Pty Limited Procédé pour la formulation de médicaments mixtes contre tdah
CN101318020B (zh) * 2007-06-06 2011-09-28 四川科瑞德制药有限公司 抗焦虑或/和抗抑郁的药物组合物及用途
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
GB201112987D0 (en) 2011-07-28 2011-09-14 Ge Healthcare Ltd Novel compound
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神***病を処置するための方法および組成物
US9463186B2 (en) 2013-04-15 2016-10-11 Northwestern University Treatment for dopaminergic disorders
CN104892589A (zh) 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
US11426366B2 (en) 2015-05-15 2022-08-30 Arizona Board Of Regents On Behalf Of The Universsity Of Arizona Compositions and methods for treating motor disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008148A1 (fr) * 1989-01-23 1990-07-26 Pfizer Inc. Agents anxiolytiques bis-aza-bicycliques
WO1992000075A1 (fr) * 1990-06-29 1992-01-09 Pfizer Inc. Derives de pyridopyrazine utilises dans le traitement de l'abus et de la dependance de substances
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
GB9408084D0 (en) * 1994-04-23 1994-06-15 Boots Co Plc Medical treatment
CA2192975C (fr) * 1994-06-14 1999-09-21 Anton F. Fliri Derives de la benzimidazolone a activite dopaminergique centrale
US5877183A (en) * 1996-06-06 1999-03-02 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.

Also Published As

Publication number Publication date
EE200100179A (et) 2002-10-15
AU5383199A (en) 2000-04-10
US20010034347A1 (en) 2001-10-25
US6608064B2 (en) 2003-08-19
TW518225B (en) 2003-01-21
TR200402083T2 (tr) 2004-10-21
IS5852A (is) 2001-02-20
US6300329B1 (en) 2001-10-09
EP1115402A1 (fr) 2001-07-18
CZ20011006A3 (cs) 2001-09-12
BG105445A (en) 2001-12-29
AU760230B2 (en) 2003-05-08
NZ509855A (en) 2003-04-29
OA11653A (en) 2004-12-08
HUP0103691A2 (hu) 2002-02-28
PE20001084A1 (es) 2000-10-18
KR20030088512A (ko) 2003-11-19
PA8482001A1 (es) 2000-05-24
AP2001002102A0 (en) 2001-03-31
YU21701A (sh) 2004-07-15
CA2344670A1 (fr) 2000-03-30
NO20011409D0 (no) 2001-03-20
AR029739A1 (es) 2003-07-16
HN1999000146A (es) 2000-11-11
IL164839A0 (en) 2005-12-18
AP1456A (en) 2005-09-30
PL346904A1 (en) 2002-03-11
TNSN99177A1 (fr) 2005-11-10
MA26690A1 (fr) 2004-12-20
KR100468340B1 (ko) 2005-01-27
DZ2894A1 (fr) 2003-12-15
JP2002526448A (ja) 2002-08-20
HRP20010209A2 (en) 2002-04-30
WO2000016777A1 (fr) 2000-03-30
EA200100204A1 (ru) 2001-08-27
IL141507A0 (en) 2002-03-10
KR20010075222A (ko) 2001-08-09
GT199900154A (es) 2001-03-06
NO20011409L (no) 2001-03-28
BR9913975A (pt) 2001-06-19
TR200101357T2 (tr) 2001-08-21
GEP20033081B (en) 2003-10-27
SK3592001A3 (en) 2001-12-03
EA200301063A1 (ru) 2004-12-30
KR20040054752A (ko) 2004-06-25
HUP0103691A3 (en) 2003-01-28
CN1319013A (zh) 2001-10-24
CO5140075A1 (es) 2002-03-22
MY127939A (en) 2007-01-31

Similar Documents

Publication Publication Date Title
ID28028A (id) Zat-zat farmasi untuk pengobatan penyakit parkinson, adhd dan mikroadenomas
DE69929996D1 (de) Pharmazeutisches mittel zur behandlung von diabetes
ID30393A (id) Senyawa tienopirimidina, pembuatan dan penggunaannya
ID22852A (id) Bahan-bahan biokontrol antifungi, proses untuk membuatnya dan memperlakukannya
ATE285767T1 (de) Kombinationstherapie, enthaltend atorvastatin und bluddrucksenkendes mittel
PT1037615E (pt) Composicoes e metodos para o tratamento da desordem de deficiencia de atencao e desordem de deficiencia de atencao/hiperactividade com metilfenidato
EE9900453A (et) Graanul, farmatseutiline doseerimisvorm, graanulite valmistamismeetod ja ravimiga kaetud graanulid
DK1117645T3 (da) Arylsubstituerede propanolaminderivater, fremgangsmåder til fremstilling deraf, lægemidler indeholdende disse forbindelser og anvendelse deraf
BR0008053B1 (pt) processo e aparelho para fabricaÇço de artigos absorventes descartÁveis.
ID21863A (id) Senyawa kinolin dan kinazolin yangberguna dalam terapi, khususnya dalam pengobatan heperplasia prostatik jinak
ID26707A (id) Katalisator untuk produksi-olefin dan metode produksi-olefin
ID21332A (id) Metode dan komposisi untuk pengobatan dan pencegahan hiperurikemia
ID23514A (id) Monolefinik c5 mononitril, pembuatan dan penggunaan darinya
DE69805853D1 (de) Modifizierte lithium-vanadium-oxidelektrodenmaterialien, produkte und verfahren
ID20137A (id) Turunan propanolamina, proses pembuatannya, sediaan farmasi yang mengandung senyawa ini, dan penggunannya
ID18244A (id) Komposisi polipropilena dan metoda pembuatannya dan katalis untuk
DE69628162D1 (de) Polymermaterial, medizinisches material und flüssige polymerzusammensetzung
ID29547A (id) Metoda dan komposisi untuk pencegahan dan pengobatan tuberkulosis
EA200101260A1 (ru) Способ изменения физико-химических и/или биологических свойств вещества
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
ID24173A (id) 1,2,3,4,5,6 heksahidro-2-6-metano-3-benzazosin-10-ol, proses pembuatan dan penggunannya untuk obat-obatan
ID26985A (id) Amina-amina polisiklik tiazolidin-2-ilidena, proses pembuatannya, dan penggunaannya a sebagai bahas farmasi
EE200200199A (et) N-guanidinoalküülamiid, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaat ning raviotstarbeline kasutamine
GB2341092B (en) Composition for the removal of biological and organic substances
ID28894A (id) Metoda dan komposisi untuk perlakuan terhadap penyakit gangguan gastro-esophageal